Irhythm Technologies ( (IRTC) ) has released its Q3 earnings. Here is a breakdown of the information Irhythm Technologies presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
iRhythm Technologies, Inc. is a digital healthcare company specializing in wearable biosensors and data analytics to provide actionable insights for cardiac care. In its third-quarter 2025 financial results, iRhythm reported a significant revenue increase of 30.7% year-over-year, reaching $192.9 million, driven by strong demand for its Zio services and expansion into international markets. The company also achieved a gross margin of 71.1%, reflecting operational efficiencies and increased service volumes.
Key financial highlights include a reduction in net loss to $5.2 million, a notable improvement from the $46.2 million loss in the same period the previous year, attributed to revenue growth and cost management. Operating expenses decreased slightly, while the company maintained a robust cash position with $565.2 million in unrestricted cash and marketable securities.
Strategically, iRhythm continues to expand its core business and innovate with new solutions, including the submission of its next-generation Zio MCT solution to the FDA and advancements in sleep diagnostics. The company also highlighted the clinical value of its Zio services through recent studies and upcoming presentations at the American Heart Association Scientific Sessions.
Looking ahead, iRhythm projects full-year 2025 revenue between $735 million and $740 million, with an adjusted EBITDA margin of 8.25% to 8.75%. The company remains focused on scaling its platform and expanding its market presence, aiming for continued growth and operational efficiency.